Skip to main content
. 2013 Feb 12;108(5):1119–1125. doi: 10.1038/bjc.2013.51

Table 2. Relationship between NY-ESO-1 antibody positivity and clinicopathological features in gastric cancer patients.

Variable
NY-ESO-1 Ab
P-value*
  Negative Positive  
Gender
Male 223 (86.4) 35 (13.6) 0.04307
Female
99 (94.3)
6 (5.7)
 
Age (years)
>65 178 (88.6) 23 (11.4) 0.9209
<65
144 (88.9)
18 (11.1)
 
Histological type
Differentiated 143 (89.4) 17 (10.6) 0.5605
Undifferentiated
132 (87.4)
19 (12.6)
 
Depth of tumour invasion
cT1–T2 193 (92.8) 15 (7.2) 0.0044
cT3–T4
129 (83.2)
26 (16.8)
 
Lymph node metastasis
Negative 196 (97.0) 6 (3.0) <0.001
Positive
126 (78.3)
35 (21.7)
 
Distant metastasis
Negative 277 (91.1) 27 (8.9) <0.001
Positive
45 (76.3)
14 (23.7)
 
Stage
I–II 213 (96.4) 8 (3.6) <0.001
III–IV 109 (76.8) 33 (23.2)  

Abbreviations: Ab=antibody.

Fisher's exact test was used for the statistical analysis.

Values within parentheses are percentages.